Researchers are exploring the use of multiplex engineering and multifunction T cells to develop precise and effective immunotherapies. This involves leveraging technologies such as CRISPR-Cas for genome editing, with potential applications in fields including cancer treatment and plant genetics. The goal of these efforts appears to be improving the efficacy, safety, and accessibility of therapies like CAR-T cell therapy.